Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.

Evidence report/technology assessment (Summary)

Volumn , Issue 82, 2003, Pages 1-6

  Shekelle, P ^a   Morton, S ^a   Atkinson, S ^a   Suttorp, M ^a   Tu, W ^a   Heidenreich, P ^a   Gubens, M ^a   Maglione, M ^a   Jungvig, L ^a   Roth, E ^a   Newberry, S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; META ANALYSIS; NEGRO; STATISTICS; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0642282541     PISSN: 1530440X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)